Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Sanofi (SNY : NSDQ)
 
 • Company Description   
Sanofi-Aventis manufactures & markets prescription drugs across countries. It focuses on major therapeutic areas such as multiple sclerosis, cardiovascular, immunology, neurology, oncology, rare blood disorders & diabetes, etc. By taking Genzyme Corporation as a subsidiary, it added products like Cerezyme, Myozyme/Lumizyme & Fabrazyme to its portfolio. Sanofi has become a major player in the CHC sector. It acquired many companies i.e. Ablynx & Bioverativ, Synthorx & Principia & Translate Bio and Kadmon. It has collaborated with companies like Regeneron among others. It develops and markets Dupixent, Kevzara & Libtayo in collaboration with Regeneron. Sanofi, along with Regeneron, is now solely responsible for Praluent marketing in & outside the U.S. Sanofi operates through 3 Global Business Units: Specialty Care (neurology & immunology, rare diseases, rare blood disorders & oncology), Vaccines & General Medicines (diabetes, cardiovascular & established products) and Consumer Healthcare, a standalone unit.

Number of Employees: 91,573

 
 • Price / Volume Information   
Yesterday's Closing Price: $54.42 Daily Weekly Monthly
20 Day Moving Average: 1,751,800 shares
Shares Outstanding: 2,521.67 (millions)
Market Capitalization: $137,229.33 (millions)
Beta: 0.54
52 Week High: $58.10
52 Week Low: $36.91
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week 14.26% 10.70%
12 Week 13.97% 5.61%
Year To Date 12.37% 5.63%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
46 AVENUE DE LA GRANDE ARMEE
-
PARIS,I0 75017
-
ph: 33-1-53-77-44-00
fax: 33-1-53-77-43-03
ir@sanofi.com http://www.sanofi.com
 
 • General Corporate Information   
Officers
Paul Hudson - Chief Executive Officer
Serge Weinberg - Chairman
Christophe Babule - Executive Vice President; Chief Financial Officer
Rachel Duan - Director
Lise Kingo - Director

Peer Information
Sanofi (AGN.)
Sanofi (ABBV)
Sanofi (NVO)
Sanofi (LLY)
Sanofi (RHHBY)
Sanofi (JNJ)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: Large Cap Pharma
Sector: Medical
CUSIP: 80105N105
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 12/01/22
Next Expected EPS Date: 04/27/23
Share - Related Items
Shares Outstanding: 2,521.67
Most Recent Split Date: (:1)
Beta: 0.54
Market Capitalization: $137,229.33 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 2.32%
Current Fiscal Quarter EPS Consensus Estimate: $1.10 Indicated Annual Dividend: $1.26
Current Fiscal Year EPS Consensus Estimate: $4.40 Payout Ratio: 0.29
Number of Estimates in the Fiscal Year Consensus: 6.00 Change In Payout Ratio: -0.06
Estmated Long-Term EPS Growth Rate: 7.39% Last Dividend Paid: NA - $0.00
Next EPS Report Date: 04/27/23  
 

 • Fundamental Ratios
P/E
Current FY Estimate: 12.36
Trailing 12 Months: 12.57
PEG Ratio: 1.67
Price Ratios
Price/Book: 1.73
Price/Cash Flow: 9.46
Price / Sales: 3.04
EPS Growth
vs. Year Ago Period: 10.13%
vs. Previous Quarter: -40.00%
Sales Growth
vs. Year Ago Period: -4.19%
vs. Previous Quarter: -12.95%
ROE
03/31/23 - 28.00
12/31/22 - 27.03
09/30/22 - 25.99
ROA
03/31/23 - 16.50
12/31/22 - 15.66
09/30/22 - 15.06
Current Ratio
03/31/23 - 1.42
12/31/22 - -
09/30/22 - 1.29
Quick Ratio
03/31/23 - 1.05
12/31/22 - -
09/30/22 - 0.34
Operating Margin
03/31/23 - 24.03
12/31/22 - 23.32
09/30/22 - 22.57
Net Margin
03/31/23 - 15.70
12/31/22 - 15.10
09/30/22 - 16.60
Pre-Tax Margin
03/31/23 - 22.96
12/31/22 - -
09/30/22 - -
Book Value
03/31/23 - 31.40
12/31/22 - -
09/30/22 - 29.98
Inventory Turnover
03/31/23 - 1.82
12/31/22 - -
09/30/22 - -
Debt-to-Equity
03/31/23 - 0.20
12/31/22 - -
09/30/22 - 0.22
Debt-to-Capital
03/31/23 - 16.51
12/31/22 - -
09/30/22 - 18.27
 

Powered by Zacks Investment Research ©